EUVIMEDEUVIMED entdecken
Kohortenstudie

Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study

Liying Du, Liman Huo, Juan Hou, Xiajin Zhou, Mingfeng Liu, Teng Guo, Wei Wang, Huihui Chen, Xinran Chen iD

Biopharmaceutics & Drug Disposition · 2023-04 · 44 (2) · 175-182

DOI: 10.1002/bdd.2354 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 28.03.2023. Verfasst von Liying Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: The key project plan for health and medical science research in Hebei Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti‐infectious efficacy. Compared with the low norvancomycin trough concentration group (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKidney Failure, ChronicHumansRetrospective StudiesRenal Dialysis

Stichwörter der Autor:innen

blood concentration monitoringend stage kidney diseasehemodialysisinfectionnorvancomycin

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang, China.
  • Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

ORCID-Profile: Xinran Chen

Förderung

  • The key project plan for health and medical science research in Hebei Provincial Health Commission

Zitieren

APA

Du, L., Huo, L., Hou, J., Zhou, X., Liu, M., Guo, T., Wang, W., Chen, H., & Chen, X. (2023). Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition, 44(2), 175-182. https://doi.org/10.1002/bdd.2354

Vancouver

Du L, Huo L, Hou J, Zhou X, Liu M, Guo T, et al. Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition. 2023;44(2):175-182. doi:10.1002/bdd.2354

BibTeX
@article{Du2023,
  author = {Du, Liying and Huo, Liman and Hou, Juan and Zhou, Xiajin and Liu, Mingfeng and Guo, Teng and Wang, Wei and Chen, Huihui and Chen, Xinran},
  title = {Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  volume = {44},
  number = {2},
  pages = {175--182},
  doi = {10.1002/bdd.2354}
}
Kostenlos starten →